This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as well as the possible impacts of these factors on the outcome of progression, exacerbations, and mortality in patients with ILD associated to CTD.
Study Type
OBSERVATIONAL
Enrollment
312
Colegio Mexicano de Reumatología
Mexico City, Mexico
RECRUITINGTime to first exacerbation: time in months elapsed until the first exacerbation from the diagnosis
Time frame: up to 13 years
Number of exacerbation per year (frequency of exacerbation)
Time frame: up to 13 years
Percent of pulmonary fibrosis: grade of parenchymal involvement evidenced by high-resolution computed tomography (HRCT)
Time frame: up to 13 years
Change in 6-minute walk tests (6-MWT) over time
Time frame: up to 13 years
King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score change over time
Time frame: up to 13 years
Saint George Respiratory Questionnaire (SGRQ)-I score change over time
Time frame: up to 13 years
Possibility to have an exacerbation and/or progression in pulmonary fibrosis, sorted by rheumatic disease type (rheumatoid arthritis (RA), connective tissue disease (CTD), spondyloarthritis (SpA) and Sarcoidosis)
Time frame: up to 13 years
Frequency of use of diagnostic tools (laboratory, cabinet)
Time frame: up to 13 years
Progression of pulmonary fibrosis by treatment received identified by HRCT patterns, lung function, activity score and damage index
Time frame: up to 13 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.